{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:36:42Z","timestamp":1777934202477,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T00:00:00Z","timestamp":1352937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:p>Chronic myeloid leukemia is characterized by a unique reciprocal translocation between chromosomes 9 and 22 resulting in deregulated tyrosine kinase activity. Tyrosine kinase inhibitors, such as imatinib, dasatinib, and nilotinib have revolutionized treatment of Chronic myeloid leukemia. However, tyrosine kinase inhibitors\u2019 use has presented new challenges in managing both acute and chronic toxicities, particularly \u2018off-target\u2019 toxicities like pleural effusion. Pleural effusions are seen less often with imatinib and very rarely with nilotinib. A 66-year-old male presented to emergency department with complaints of mild chest pain and dyspnea of 3 days duration with progressive worsening, including dyspnea at rest. Patient was currently taking nilotinib after failing imatinib for chronic myeloid leukemia. Nilotinib was put on hold. After exclusion of cardiac and pulmonary etiologies patient was treated for community acquired pneumonia with minimal improvement. Despite the very low incidence of pleural effusion with nilotinib (&lt;1%), he was started on 20\u2009mg of prednisone PO for 3 days. Patient had a dramatic improvement within 48\u2009h after beginning prednisone. This treatment approach suggests that pleural effusions associated with nilotinib can be successfully treated in the same way as pleural effusions associated with dasatinib.<\/jats:p>","DOI":"10.1177\/1078155212447530","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T21:57:26Z","timestamp":1353016646000},"page":"175-177","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Successful treatment of nilotinib-induced pleural effusion with prednisone"],"prefix":"10.1177","volume":"19","author":[{"given":"K","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Quillen College of Medicine, East Tennessee State University, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JB","family":"Bossaer","sequence":"additional","affiliation":[{"name":"Gatton College of Pharmacy, East Tennessee State University, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Patel","sequence":"additional","affiliation":[{"name":"Quillen College of Medicine, East Tennessee State University, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Quillen College of Medicine, East Tennessee State University, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,11,15]]},"reference":[{"key":"bibr1-1078155212447530","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"bibr2-1078155212447530","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032"},{"key":"bibr3-1078155212447530","unstructured":"Sprycel [package insert]. Bristol-Myers Squibb Co., Princeton, NJ; October 2011, http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf (accessed 1 December 2011)."},{"key":"bibr4-1078155212447530","unstructured":"Gleevec [package insert]. Novartis Pharmaceuticals Corp., East Hanover, NJ; April 2011, http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gleevec_tabs.pdf (accessed 1 December 2011)."},{"key":"bibr5-1078155212447530","unstructured":"Tasigna [package insert]. Novartis Pharmaceuticals Corp., East Hanover, NJ; October 2011, http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf (accessed 1 December 2011)."},{"key":"bibr6-1078155212447530","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"bibr7-1078155212447530","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328338c486"},{"key":"bibr8-1078155212447530","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0110-4"},{"key":"bibr9-1078155212447530","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155212447530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155212447530","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155212447530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:35Z","timestamp":1777688075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155212447530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1177\/1078155212447530"],"URL":"https:\/\/doi.org\/10.1177\/1078155212447530","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,15]]}}}